We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
well that was brutal, are we now going to find out why??
The announcement today was good. I will average down if I get the opportunity.
Nomads don't protect unsophisticated investors, we are left out for the wolves
If there is a placing announced today or tomorrow and Finncap are involved, that will answer a lot of questions about today's price action.....
Very disappointed by the SP reaction to the presentation, I guess investors were expecting the perfect solution immediately. This is still a fantastic product and I can see a really strong demand for it. Covid will still be around this winter and early next year when the product becomes available. There is still very little awareness of the MicrotoxBT and I can easily see the SP rising again as news spreads around and people realise just how useful a tool this is
I’m quite happy I brought the t-shirt (@ sub 2 btw), still wearing & loving it !
Que? Where have you been, we've all read that, seen the movie, and wished we'd not bought the T-shirt.
Integumen PLC (to be renamed DeepVerge PLC)
("Integumen" or "Company")
Unveiling of new COVID-19 personalised real-time Breath Test and Digital Health Pass Platform
COVID-19 wastewater Microtox ready for beta testing
Heads of Agreement with Avacta and Aptamer Group for commercial scale supply of SARS-CoV-2 binding agents
Integumen today announces progress for its COVID-19 wastewater detection system, Microtox PD, in collaboration with Modern Water plc ("Modern Water"), Avacta Group plc ("Avacta") and Aptamer Group Limited ("Aptamer"). The Company also today announces the unveiling of a new personalised COVID-19 breath test, Microtox BT, and its complementary Digital Health Pass platform.
Integumen is working with a consortium of companies collaborating to find solutions in the fight against COVID-19 pandemic. The consortium includes Modern Water, Avacta, Aptamer and a major global provider of innovative technology and services for the data era.
Microtox BT and Digital Health Pass - on the spot triaging of COVID-19 infections offer potential to re-open the economy
Integumen recognised that in collaboration with Modern Water , Avacta and Aptamer Group, its real-time detection and alert system could be adapted to detect the level of infection of coronavirus in a breath sample. Adapting the wastewater test, Microtox PD, the Company has designed, built and tested a prototype, Microtox BT, which can analyse the breath and detect the spike protein of SARS-CoV-2 in real-time for those with a high viral load. Microtox BT has undergone extensive internal testing and will now transition to the University of Aberdeen containment level 3 laboratory, to undergo tests directly on the virus followed by a joint trial of up to 5,000 participants in parallel with third parties using reverse transcription polymerase chain reaction ("rtPCR")[i] and Antigen tests. Results are anticipated before the end of the year and Microtox BT is expected to be a Class 1 medical device[ii].
The Company believes Microtox BT has the potential to enable instant real-time testing of people within the community. This could be capable of providing daily triaging of everyone who may or may not demonstrate levels of infection. To "open the economy", Integumen has incorporated a 24 hour Digital Health Pass that indicates if the person tests positive or negative for infection. Matched with blockchain secure date and time stamp of the test, the Company believes Microtox BT and the Digital Health Pass using "one second" QR Code scanners could potentially contribute to enabling the economy to re-open with personalised go/no go entry into venues such as work, events, social locations, public transport and airports.